

Evolving landscape of tumor molecular profiling for personalized medicine: a comprehensive review

Expert Opinion on Drug Metabolism and Toxicology
12, 911-922

DOI: [10.1080/17425255.2016.1196187](https://doi.org/10.1080/17425255.2016.1196187)

Citation Report

| # | ARTICLE | IF | CITATIONS |
|----|---|-----|-----------|
| 1 | Opportunities and Challenges for Drug Development: Public-Private Partnerships, Adaptive Designs and Big Data. <i>Frontiers in Pharmacology</i> , 2016, 7, 461. | 1.6 | 60 |
| 2 | Integrating precision cancer medicine into healthcare policy, practice, and research challenges. <i>Genome Medicine</i> , 2016, 8, 108. | 3.6 | 46 |
| 3 | Will New Genetic Techniques Like Exome Sequencing and Others Obviate the Need for Clinical Expertise? Yes. <i>Movement Disorders Clinical Practice</i> , 2017, 4, 36-38. | 0.8 | 1 |
| 4 | Immunogenomics: using genomics to personalize cancer immunotherapy. <i>Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin</i> , 2017, 471, 209-219. | 1.4 | 7 |
| 5 | Exosomes in Cancer Nanomedicine and Immunotherapy: Prospects and Challenges. <i>Trends in Biotechnology</i> , 2017, 35, 665-676. | 4.9 | 313 |
| 6 | Chemotherapy for advanced gastric cancer. <i>The Cochrane Library</i> , 2017, 2017, CD004064. | 1.5 | 662 |
| 7 | Pharmacogenetics and Personalized Medicine. , 2017, , 149-168. | | 1 |
| 8 | Antimicrobial Peptides As Biologic and Immunotherapeutic Agents against Cancer: A Comprehensive Overview. <i>Frontiers in Immunology</i> , 2017, 8, 1320. | 2.2 | 102 |
| 9 | Functional Roles and Therapeutic Applications of Exosomes in Hepatocellular Carcinoma. <i>BioMed Research International</i> , 2017, 2017, 1-8. | 0.9 | 23 |
| 10 | Molecular epidemiology of lung cancer in Iran: implications for drug development and cancer prevention. <i>Journal of Human Genetics</i> , 2018, 63, 783-794. | 1.1 | 23 |
| 11 | Pan-HDAC inhibition by panobinostat mediates chemosensitization to carboplatin in non-small cell lung cancer via attenuation of EGFR signaling. <i>Cancer Letters</i> , 2018, 417, 152-160. | 3.2 | 69 |
| 12 | Value of a molecular screening program to support clinical trial enrollment in Asian cancer patients: The Integrated Molecular Analysis of Cancer (IMAC) Study. <i>International Journal of Cancer</i> , 2018, 142, 1890-1900. | 2.3 | 15 |
| 13 | Art and Challenges of Precision Medicine: Interpreting and Integrating Genomic Data Into Clinical Practice. <i>American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting</i> , 2018, 38, 546-553. | 1.8 | 26 |
| 14 | Novel group of tyrosyl-DNA-phosphodiesterase 1 inhibitors based on disaccharide nucleosides as drug prototypes for anti-cancer therapy. <i>Journal of Enzyme Inhibition and Medicinal Chemistry</i> , 2018, 33, 1415-1429. | 2.5 | 18 |
| 15 | Detection of somatic mutations in cell-free DNA in plasma and correlation with overall survival in patients with solid tumors. <i>Oncotarget</i> , 2018, 9, 10259-10271. | 0.8 | 29 |
| 16 | Liquid Biopsy: From Basic Research to Clinical Practice. <i>Advances in Clinical Chemistry</i> , 2018, 83, 73-119. | 1.8 | 49 |
| 17 | Chemotherapy Resistance. , 2018, , 87-104. | | 0 |
| 18 | Real-Time Tumor Gene Expression Profiling to Direct Gastric Cancer Chemotherapy: Proof-of-Concept Trial. <i>Clinical Cancer Research</i> , 2018, 24, 5272-5281. | 3.2 | 20 |

| # | ARTICLE | IF | CITATIONS |
|----|---|-----|-----------|
| 19 | Immune checkpoint inhibitors plus chemotherapy versus chemotherapy or immunotherapy for first-line treatment of advanced non-small cell lung cancer: a generic protocol. The Cochrane Library, 0, , . | 1.5 | 6 |
| 20 | Pan-CDK inhibition augments cisplatin lethality in nasopharyngeal carcinoma cell lines and xenograft models. Signal Transduction and Targeted Therapy, 2018, 3, 9. | 7.1 | 29 |
| 21 | A Next-Generation Sequencing Primer—How Does It Work and What Can It Do?. Academic Pathology, 2018, 5, 2374289518766521. | 0.7 | 60 |
| 22 | Therapy for glioblastoma: is it working?. Drug Discovery Today, 2019, 24, 1193-1201. | 3.2 | 86 |
| 23 | Urinary exosomal shuttle RNA: Promising cancer diagnosis biomarkers of lower urinary tract. International Journal of Biological Markers, 2019, 34, 101-107. | 0.7 | 13 |
| 24 | The antitumor activity of 4,4-bipyridinium amphiphiles. RSC Advances, 2019, 9, 33023-33028. | 1.7 | 2 |
| 25 | Clinical Utility of Real-Time Targeted Molecular Profiling in the Clinical Management of Ovarian Cancer: The ALLOCATE Study. JCO Precision Oncology, 2019, 3, 1-18. | 1.5 | 0 |
| 26 | Health Care Delivery for Metastatic Hormone-sensitive Prostate Cancer Across the Globe. European Urology Focus, 2019, 5, 155-158. | 1.6 | 13 |
| 27 | Role of tumor-derived exosomes in cancer metastasis. Biochimica Et Biophysica Acta: Reviews on Cancer, 2019, 1871, 12-19. | 3.3 | 82 |
| 28 | Gene Networks Constructed Through Simulated Treatment Learning can Predict Proteasome Inhibitor Benefit in Multiple Myeloma. Clinical Cancer Research, 2020, 26, 5952-5961. | 3.2 | 5 |
| 29 | Precision Medicine in Oncology: In Vitro Drug Sensitivity and Resistance Test (DSRT) for Selection of Personalized Anticancer Therapy. Advanced Therapeutics, 2020, 3, 1900100. | 1.6 | 25 |
| 30 | Current Statistical Considerations and Regulatory Perspectives on the Planning of Confirmatory Basket, Umbrella, and Platform Trials. Clinical Pharmacology and Therapeutics, 2020, 107, 1059-1067. | 2.3 | 61 |
| 31 | Miniaturized Drug Sensitivity and Resistance Test on Patient-Derived Cells Using Droplet-Microarray. SLAS Technology, 2021, 26, 274-286. | 1.0 | 11 |
| 32 | Extracellular Vesicles: A Novel Tool Facilitating Personalized Medicine and Pharmacogenomics in Oncology. Frontiers in Pharmacology, 2021, 12, 671298. | 1.6 | 16 |
| 33 | Dynamic multidisciplinary team discussions can improve the prognosis of metastatic castration-resistant prostate cancer patients. Prostate, 2021, 81, 721-727. | 1.2 | 15 |
| 34 | A new basket trial design based on clustering of homogeneous subpopulations. Journal of Biopharmaceutical Statistics, 2021, 31, 425-447. | 0.4 | 5 |
| 35 | Epigenetic derepression converts PPAR δ into a druggable target in triple-negative and endocrine-resistant breast cancers. Cell Death Discovery, 2021, 7, 265. | 2.0 | 7 |
| 36 | Time-varying prognostic effects of primary tumor sidedness and grade after curative liver resection for colorectal liver metastases. Surgical Oncology, 2021, 38, 101586. | 0.8 | 4 |

| # | ARTICLE | IF | CITATIONS |
|----|--|-----|-----------|
| 37 | Host defense peptides as immunomodulators: The other side of the coin. <i>Peptides</i> , 2021, 146, 170644. | 1.2 | 11 |
| 38 | EGFR kinase inhibitors and gastric acid suppressants in EGFR-mutant NSCLC: a retrospective database analysis of potential drug interaction. <i>Oncotarget</i> , 2016, 7, 85542-85550. | 0.8 | 30 |
| 39 | Identification of serum proteins and multivariate models for diagnosis and therapeutic monitoring of lung cancer. <i>Oncotarget</i> , 2017, 8, 18901-18913. | 0.8 | 24 |
| 41 | Comprehensive tumor profiling-guided therapy in rare or refractory solid cancer: A feasibility study in daily clinical practice. <i>Bulletin Du Cancer</i> , 2020, 107, 410-416. | 0.6 | 0 |
| 42 | A Novel Approach on Leukodepletion Filters: Investigation of Synergistic Anticancer Effect of Purified Î±-Defensins and Nisin. <i>Advanced Pharmaceutical Bulletin</i> , 2021, 11, 378-384. | 0.6 | 4 |
| 43 | Ketogenic Diet as Adjunctive Therapy for Malignant Brain Cancer. , 2022, , 125-153. | | 0 |
| 44 | Multidisciplinary Team (MDT) Discussion Improves Overall Survival Outcomes for Metastatic Renal Cell Carcinoma Patients. <i>Journal of Multidisciplinary Healthcare</i> , 0, Volume 16, 503-513. | 1.1 | 2 |
| 45 | Transcriptomic Analysis of CRISPR/Cas9-Mediated PARP1-Knockout Cells under the Influence of Topotecan and TDP1 Inhibitor. <i>International Journal of Molecular Sciences</i> , 2023, 24, 5148. | 1.8 | 2 |
| 48 | Circulating Tumor DNA in Lymphoma. <i>Molecular Pathology Library</i> , 2023, , 395-426. | 0.1 | 0 |